Yangambin
Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF); it has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels.
Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Phytomedicine.2019, 65:153089
Agronomy2022, 12(10), 2426.
Food Chem.2019, 278:683-691
Molecules.2018, 23(3):E615
Vietnam Journal of Food Control.2022, 5(2): 115-128.
Molecules.2020, 25(18),4089.
Food Chem.2018, 252:207-214
Biol Pharm Bull.2017, 40(6):797-806
Current Topics in Nutraceutical Research2021, 19(1),p90-105.
Biol Pharm Bull.2020, 43(10):1534-1541.
Related and Featured Products
Phytomedicine. 1996 Jan;2(3):235-42.
Antagonistic effect of yangambin on platelet-activating factor (PAF)-induced cardiovascular collapse.[Pubmed:
23194622]
The cardiovascular protective effects of Yangambin, a novel and specific naturally-occurring platelet activating factor (PAF) receptor antagonist, were investigated in the pentobarbital anesthetized and artificially ventilated rat.
METHODS AND RESULTS:
Yangambin (3-30 mg kg(-1)) as well as the reference PAF antagonist WEB 2086 (0.1-1.0 mg kg(-1)) prevented the circulatory collapse elicited by the intravenous administration of PAF (0.5 μg kg(-1)), in a dose-dependent manner. Yangambin did not interfere with the hypotensive effect of several endogenous vasoactive mediators such as acetylcholine, bradykinin, histamine and serotonin. Moreover, when adminstered as a post-treatment the antagonist showed the ability to reverse the cardiovascular effects induced by PAF (1.0 μg kg(-1)). The protective effect of Yangambin showed to have a duration of action of more than 2 hours.
CONCLUSIONS:
It is concluded that Yangambin is a selective antagonist of the cardiovascular effects of PAF and therefore constitutes a potential therapeutic agent in different shock states where abnormal PAF release is supposed to play an important role.
Molecules. 2014 May 23;19(5):6863-76.
Calcium influx inhibition is involved in the hypotensive and vasorelaxant effects induced by yangambin.[Pubmed:
24858272 ]
The pharmacological effects on the cardiovascular system of Yangambin, a lignan isolated from Ocotea duckei Vattimo (Lauraceae), were studied in rats using combined functional and biochemical approaches.
METHODS AND RESULTS:
In non-anaesthetized rats, Yangambin (1, 5, 10, 20, 30 mg/kg, i.v.) induced hypotension (-3.5 ± 0.2; -7.1 ± 0.8; -8.9 ± 1.3; -14 ± 2.3, -25.5% ± 2.6%, respectively) accompanied by tachycardia (5.9 ± 0.5; 5.9 ± 1.6; 8.8 ± 1.4; 11.6, 18.8% ± 3.4%, respectively). In isolated rat atria, Yangambin (0.1 µM-1 mM) had very slight negative inotropic (Emax = 35.6% ± 6.4%) and chronotropic effects (Emax = 10.2% ± 2.9%). In endothelium-intact rat mesenteric artery, Yangambin (0.1 µM-1 mM) induced concentration-dependent relaxation (pD2 = 4.5 ± 0.06) of contractions induced by phenylephrine and this effect was not affected by removal of the endothelium. Interestingly, like nifedipine, the relaxant effect induced by Yangambin was more potent on the contractile response induced by KCl 80 mM (pD2 = 4.8 ± 0.05) when compared to that induced by phenylephrine. Furthermore, Yangambin inhibited CaCl2-induced contractions in a concentration-dependent manner. This lignan also induced relaxation (pD2 = 4.0 ± 0.04) of isolated arteries pre-contracted with S(-)-Bay K 8644. In fura-2/AM-loaded myocytes of rat mesenteric arteries, Yangambin inhibited the Ca2+ signal evoked by KCl 60 mM.
CONCLUSIONS:
In conclusion, these results suggest that the hypotensive effect of Yangambin is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels.
Phytother Res. 2005 Apr;19(4):282-6.
Central nervous system activity of yangambin from Ocotea duckei Vattimo (Lauraceae) in mice.[Pubmed:
16041767 ]
This work presents behavioral effects of Yangambin isolated from the leaves of Ocotea duckei on open field, rota rod, barbiturate sleeping time, forced swimming and elevated plus maze test in mice.
METHODS AND RESULTS:
Yangambin was intraperitoneally administered to male mice at single doses of 12.5, 25 and 50 mg/kg. The results showed that Yangambin in the doses of 25 and 50 mg/kg decreased the locomotor activity and the number of rearing. However, no change was observed in the rota rod test between the Yangambin groups as compared to the control group. Reduction on the sleep latency and a prolongation of the sleeping time induced by pentobarbital was observed only with the Yangambin dose of 50 mg/kg. In the forced swimming test, Yangambin (25 and 50 mg/kg) increased the immobility time. Yangambin, in the doses of 25 and 50 mg/kg, decreased the number of entries and the time of permanence in the open arms of the elevated plus maze test. However, this effect can not be related to anxiogenic effects, but to a decrease in locomotor activity.
CONCLUSIONS:
The results showed that Yangambin presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests. These effects probably were not due to peripheral neuromuscular blockade, since there was no alteration on the rota rod test. Also, no anxiolytic effect was observed after the treatment with Yangambin.
